Combination Treatment With BTL-899 and HPM-6000UF Devices

Sponsor
BTL Industries Ltd. (Industry)
Overall Status
Active, not recruiting
CT.gov ID
NCT05537181
Collaborator
(none)
39
3
1
9.9
13
1.3

Study Details

Study Description

Brief Summary

This study will evaluate the clinical efficacy of the BTL-899 and HPM-6000UF devices in combination for non-invasive strengthening of the core muscles and overall improvement in quality of life in elderly patients.

Condition or Disease Intervention/Treatment Phase
  • Device: BTL-899; HPM-6000UF Treatments
N/A

Detailed Description

The study is a prospective, multicenter single-arm, open-label, interventional study. The subjects will be enrolled and assigned into a single study group. Subjects will be required to complete seven (7) treatment visits and two (2) follow-up visits - 1 month and 3 months after the final treatment.

At the baseline visit, medical history will be assessed. Inclusion and exclusion criteria will be verified, and informed consent will be signed. Digital photographs will be taken, waist circumference will be measured, abdominal muscle strength will be measured with a pressure biofeedback device.

The two devices will be used separately in two different treatments. However one treatment visit can comprise both treatments. The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered. The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered. There will be three (3) visits where both treatments will be applied consecutively, starting with BTL-899, followed by the therapy with HPM-6000UF.

Study Design

Study Type:
Interventional
Actual Enrollment :
39 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of the Combination Treatment With BTL-899 and HPM-6000UF Devices for Abdominal and Pelvic Floor Muscle Strengthening and Overall Improvement in Quality of Life in Elderly Patients
Actual Study Start Date :
Feb 4, 2022
Anticipated Primary Completion Date :
Oct 1, 2022
Anticipated Study Completion Date :
Dec 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: BTL-899; HPM-6000UF Treatments

The two devices will be used separately in two different treatments. However one treatment visit can comprise both treatments. The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered. The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.

Device: BTL-899; HPM-6000UF Treatments
The two devices will be used separately in two different treatments. However one treatment visit can comprise both treatments. The BTL-899 will be applied over the abdomen, and the device will induce visible muscle contractions along with mild heating of the muscles. Four (4) treatments once a week will be delivered. The HPM-6000UF device will induce pelvic floor muscle contractions. Six (6) treatments 2-4 days apart will be delivered.

Outcome Measures

Primary Outcome Measures

  1. Assessment of core muscles strength measured by pressure biofeedback device [5 months]

  2. Assessment of subject's quality of life based on Subject Satisfaction and Experience Questionnaire [5 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
60 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Healthy male or female subjects aged 60 years or older (postmenopause when female),

  • BMI ≤35kg/m2 seeking treatment for strengthening their pelvic floor or abdominal muscles

  • Subjects should be able to understand the investigative nature of the treatment, the possible benefits and side effects, and must sign the Informed Consent Form.

  • Subjects willing and able to abstain from partaking in any concurrent treatments on abdomen and pelvic floor other than the study procedures during study participation.

  • Willingness to comply with study instructions, to return to the clinic for the required visits, and to have photographs taken.

Exclusion Criteria:
  • Electronic implants (such as cardiac pacemakers, defibrillators, and neurostimulators)

  • Metal implants in the treated area

  • Drug pumps

  • Malignant tumor

  • Pulmonary insufficiency

  • Injured or otherwise impaired muscles in the treated area

  • Cardiovascular diseases

  • Disturbance of temperature or pain perception

  • Hemorrhagic conditions

  • Septic conditions and empyema

  • Acute inflammations in the treated area

  • Systemic or local infection such as osteomyelitis and tuberculosis

  • Contagious skin disease

  • Elevated body temperature

  • Poor healing and unhealed wounds in the treatment area

  • Following recent surgical procedures when muscle contraction may disrupt the healing process

  • Graves' disease

Contacts and Locations

Locations

Site City State Country Postal Code
1 Plastic Surgical Associates Fort Collins Colorado United States 80525
2 Dermatologic Surgery Specialists Macon Georgia United States 31217
3 Men's Health Boston Chestnut Hill Massachusetts United States 02467

Sponsors and Collaborators

  • BTL Industries Ltd.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
BTL Industries Ltd.
ClinicalTrials.gov Identifier:
NCT05537181
Other Study ID Numbers:
  • BTL-899_CTUS500
First Posted:
Sep 13, 2022
Last Update Posted:
Sep 13, 2022
Last Verified:
Sep 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by BTL Industries Ltd.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 13, 2022